Magnus Financial Group LLC Acquires New Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Magnus Financial Group LLC bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 29,639 shares of the company’s stock, valued at approximately $599,000.

A number of other hedge funds have also recently made changes to their positions in TEVA. Versant Capital Management Inc lifted its position in shares of Teva Pharmaceutical Industries by 21.4% during the third quarter. Versant Capital Management Inc now owns 5,560 shares of the company’s stock valued at $112,000 after buying an additional 981 shares during the last quarter. PKO Investment Management Joint Stock Co acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $303,000. Nordea Investment Management AB boosted its stake in Teva Pharmaceutical Industries by 21.3% in the 3rd quarter. Nordea Investment Management AB now owns 124,871 shares of the company’s stock worth $2,431,000 after purchasing an additional 21,969 shares in the last quarter. MGO One Seven LLC grew its position in Teva Pharmaceutical Industries by 19.7% during the 3rd quarter. MGO One Seven LLC now owns 16,833 shares of the company’s stock worth $340,000 after purchasing an additional 2,774 shares during the last quarter. Finally, Cromwell Holdings LLC increased its stake in Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on TEVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Barclays began coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $33.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. This represents a 70.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 622,060 shares of company stock worth $17,076,965 over the last three months. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $32.36 on Friday. The stock’s 50 day simple moving average is $28.84 and its 200-day simple moving average is $21.97. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $33.42. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The company has a market cap of $37.12 billion, a PE ratio of 53.93, a price-to-earnings-growth ratio of 1.87 and a beta of 0.66.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.